{'fraction_non_alphanumeric': 0.01037344398340249, 'fraction_numerical': 0.0, 'mean_word_length': 4.75, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
The biopharmaceutical industry and new drugs for amyotrophic lateral sclerosis.

These are but a few of the controversies and pressures facing Sponsors of clinical trials in ALS. All researchers in the area share the hope that the current level of interest in clinical trials in ALS will lead to the development of effective therapies for this disease. It should be recognized that the long-term goal of all groups involved in ALS trials is the establishment of effective therapies.